NCT04397939 is a clinical trial in COVID-19, sponsored by Icahn School of Medicine at Mount Sinai.

Who is sponsoring NCT04397939?

NCT04397939 is sponsored by Icahn School of Medicine at Mount Sinai.

What condition does NCT04397939 study?

NCT04397939 studies COVID-19, Myocardial Reperfusion Injury, Cardiovascular Diseases.

Is NCT04397939 still recruiting?

NCT04397939 is currently completed. Last updated 8 March 2024.

Are results published for NCT04397939?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-03-08 · How we verify

NCT04397939

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Myocardial Injury and Major Adverse Outcomes in Patients With COVID-19

Completed Results posted Last updated 8 March 2024

What this trial tests

trial in COVID-19 in 4,695 participants. Completed in 1 March 2022.

Timeline

8 May 2020

Primary endpoint
1 March 2022

1 March 2022

Quick facts

Lead sponsor	Icahn School of Medicine at Mount Sinai
Status	Completed
Study type	OBSERVATIONAL
Enrollment	4,695
Start date	8 May 2020
Primary completion	1 March 2022
Estimated completion	1 March 2022
Sites	1 location across United States

Conditions studied

COVID-19 — all drugs for COVID-19 →
Myocardial Reperfusion Injury — all drugs for Myocardial Reperfusion Injury →
Cardiovascular Diseases — all drugs for Cardiovascular Diseases →

Sponsor

Icahn School of Medicine at Mount Sinai

Who can join

Eligibility, any sex, with COVID-19 or Myocardial Reperfusion Injury. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Death Primary · 6 months

Number of deaths at 6 months follow up

Group	Value	95% CI
Patients Without Cardiac Injury	417
Patients With Chronic Myocardial Injury	137
Patients With Acute Cardiac Injury	552

Number of Participants With Pulmonary Embolism Secondary · up to 6 months

Pulmonary embolism rate as assessed by number of participants with pulmonary embolism

Group	Value	95% CI
Patients Without Cardiac Injury	32
Patients With Chronic Myocardial Injury	4
Patients With Acute Cardiac Injury	22

Number of Participants With Acute Kidney Injury Secondary · up to 6 months

Acute injury rate as assessed by number of Participants with acute kidney injury

Group	Value	95% CI
Patients Without Cardiac Injury	99
Patients With Chronic Myocardial Injury	30
Patients With Acute Cardiac Injury	107

Number of Admissions to the Intensive Care Secondary · up to 6 months

Admission to the intensive care

Group	Value	95% CI
Patients Without Cardiac Injury	393
Patients With Chronic Myocardial Injury	64
Patients With Acute Cardiac Injury	325

Sponsor's own description

The study will analyze the incidence, clinical outcomes and predictors of myocardial injury in a large patient population with COVID-19 treated in Mount Sinai Hospital (MSH) system. In addition, the study team will explore the association between high-sensitivity troponin I (TnI) levels and clinical characteristics, biomarkers, cardiac tests data and treatment approaches to uncover the potential mechanisms responsible for COVID-19 induced myocardial injury.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Cardiac involvement in the long-term implications of COVID-19.
Satterfield BA, Bhatt DL, Gersh BJ. · · 2022 · cited 101× · PMID 34686843 · DOI 10.1038/s41569-021-00631-3

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Icahn School of Medicine at Mount Sinai trials

Trials by the same sponsor.

NCT07094308 — The LIFT-ECHO Last Mile Project · NA · not yet recruiting
NCT07291427 — Chronic Subdural Hematoma Embolization With Detachable Coils · not yet recruiting
NCT07194187 — High Intensity Focused Ultrasound (HIFU) Ablation for Treatment of Prostate Tissue in Bladder Outlet Obstruction · NA · not yet recruiting
NCT07260916 — Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation · NA · not yet recruiting
NCT07487948 — Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04397939 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Icahn School of Medicine at Mount Sinai
Last refreshed: 8 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04397939.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing